New treatment targeting RAS mutations in lung cancer
Novel inhibitor for oncogenic RAS for lung cancer
This study is looking for a new treatment for early-stage lung cancer by creating a special medicine that targets a protein called RAS, which can help stop tumor growth in patients who have been affected by smoking.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auburn University at Auburn NIH-funded |
| Lab location | 1 site (Auburn, UNITED STATES) |
| Project ID | NIH-10871863 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small molecule inhibitor that targets the RAS protein, which is often mutated in lung cancer due to tobacco exposure. By inhibiting RAS, the research aims to disrupt the signaling pathways that promote tumor growth and survival. The approach involves synthesizing and testing a new class of compounds to find effective treatments for patients with early-stage lung cancer. If successful, this could provide a new therapeutic option for those affected by this aggressive disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with early-stage lung cancer who have mutations in the RAS gene.
Not a fit: Patients with lung cancer who do not have RAS mutations or those with advanced-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for lung cancer patients with RAS mutations, potentially improving survival rates.
How similar studies have performed: Previous clinical trials have shown success with covalent inhibitors targeting specific RAS mutations, indicating potential for broader applications with this novel approach.
Where this research is happening
Auburn, UNITED STATES
- Auburn University at Auburn — Auburn, United States (Active)
Researchers
- Principal investigator: Piazza, Gary a — Auburn University at Auburn
- Study coordinator: Piazza, Gary a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.